|
Rheumatoid Arthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two models of inflammation (imiquimod-induced skin inflammationand delayed type hypersensitivity arthritis, DTHA) were induced inTNFR2-deficient (TNFR2<sup>-/-</sup> ) micewith or without transfer of purified CD4<sup>+</sup> CD25<sup>+</sup> cellsfrom wild-type (wt) mice.The evolution of the TNFR2<sup>+</sup> Tregpopulation before and after targetedtreatment was monitored in individuals with RA andSpA.
|
31609517 |
2020 |
|
Encephalomyelitis
|
0.040 |
Biomarker
|
disease |
BEFREE |
In various models of MS, including experimental autoimmune encephalomyelitis (EAE), the membrane-bound form of TNF (tmTNF), which signals primarily via TNFR2, mediates protective and reparative effects, whereas the soluble form (solTNF), which signals primarily via TNFR1, promotes pro-inflammatory and detrimental functions.
|
31785393 |
2020 |
|
Dermatitis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Imiquimod-induced skin inflammation and DTHA were aggravated in TNFR2<sup>-/-</sup> mice as compared to wt mice (p<0.05 for skin inflammation and p<0.0001 for ankle swelling during DTHA).Adoptive transfer of wtTregs into TNFR2<sup>-/-</sup> mice prevented from arthritis aggravation.
|
31609517 |
2020 |
|
Seizures
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Higher NCAM and lower TNF-R1 levels may help predict the occurrence of early seizures.
|
31677998 |
2020 |
|
Skin lesion
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Fn14 deficiency also attenuates the up-regulation of TNFR1 in skin lesions of atopic dermatitis.
|
31515807 |
2020 |
|
B-Cell Lymphomas
|
0.020 |
Biomarker
|
group |
BEFREE |
Western blotting was used to evaluate the protein levels of Nuclear factor-kappa B (NF-κB), tumor necrosis factor-alpha (TNF-α), tumor necrosis factor-alpha receptor 1 (TNFR1), cytochrome c, Bcl-2-associated X protein (Bax), B-cell lymphoma 2 (Bcl-2), and cleaved caspase-3 in the hippocampal tissue.
|
31669105 |
2020 |
|
Spondylarthritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Two models of inflammation (imiquimod-induced skin inflammationand delayed type hypersensitivity arthritis, DTHA) were induced inTNFR2-deficient (TNFR2<sup>-/-</sup> ) micewith or without transfer of purified CD4<sup>+</sup> CD25<sup>+</sup> cellsfrom wild-type (wt) mice.The evolution of the TNFR2<sup>+</sup> Tregpopulation before and after targetedtreatment was monitored in individuals with RA andSpA.
|
31609517 |
2020 |
|
Inflammatory dermatosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Imiquimod-induced skin inflammation and DTHA were aggravated in TNFR2<sup>-/-</sup> mice as compared to wt mice (p<0.05 for skin inflammation and p<0.0001 for ankle swelling during DTHA).Adoptive transfer of wtTregs into TNFR2<sup>-/-</sup> mice prevented from arthritis aggravation.
|
31609517 |
2020 |
|
Dermatitis, Atopic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Fn14 deficiency also attenuates the up-regulation of TNFR1 in skin lesions of atopic dermatitis.
|
31515807 |
2020 |
|
Eczema
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Fn14 deficiency also attenuates the up-regulation of TNFR1 in skin lesions of atopic dermatitis.
|
31515807 |
2020 |
|
polyps
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These results suggest that Polyp-Au-GO composite inhibits VSMC proliferation and TNF-R-mediated inflammatory responses.
|
31837585 |
2020 |
|
TNF receptor-associated periodic fever syndrome (TRAPS)
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Genetic analysis revealed a mutation in the TNFRSF1A gene, and the patient was diagnosed with TRAPS-associated bilateral panuveitis.
|
29256170 |
2019 |
|
TNF receptor-associated periodic fever syndrome (TRAPS)
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We identified two TRAPS patients in one family harboring a novel p.Gly87Val (G87V) mutation in addition to a p.Thr90Ile (T90I) mutation in TNFRSF1A.
|
31429073 |
2019 |
|
TNF receptor-associated periodic fever syndrome (TRAPS)
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Four Greek patients with TRAPS-like clinical features were screened for TNFRSF1A mutations by sequencing exons 2, 3 and 4.
|
31562507 |
2019 |
|
TNF receptor-associated periodic fever syndrome (TRAPS)
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
TNF receptor-associated periodic fever syndrome (TRAPS) is an autosomal dominant systemic autoinflammatory disease caused by mutations of TNF receptor superfamily member 1 A (TNFRSF1A) gene.
|
31774538 |
2019 |
|
TNF receptor-associated periodic fever syndrome (TRAPS)
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Tumor necrosis factor receptor associated periodic fever syndrome (TRAPS) is caused by heterozygote mutations in TNFRSF1A, characterized by recurrent inflammatory attacks.
|
31586650 |
2019 |
|
TNF receptor-associated periodic fever syndrome (TRAPS)
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The cryopyrin associated periodic syndrome (CAPS), the hyper IgD syndrome (HIDS) and the TNF receptor-associated periodic syndrome (TRAPS), are autoinflammatory conditions associated with mutations in the NLRP3, MVK and TNFRSF1A genes, respectively.
|
30418111 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.590 |
Biomarker
|
disease |
BEFREE |
Moreover, higher TNFR-1 and TNFR-2 was also significantly associated with CVD events and mortality in patients with type 2 diabetes.
|
31813103 |
2019 |
|
Multiple Sclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphism (rs1800693) of TNFRSF1A (type 1 tumour necrosis factor receptor) encodes a potentially anti-inflammatory soluble truncated form of the p55 receptor, which is associated with predisposition to multiple sclerosis but protection against ankylosing spondylitis (AS).
|
29535371 |
2019 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The interaction between TNF-α with TNFR1 triggers important signaling pathways inducing diverse cellular phenomena including inflammation, apoptosis, etc., and is involved in the pathogenesis and progression of numerous autoimmune diseases.
|
30414969 |
2019 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, TNFR2 agonists or TNFR1-specific antagonists hold a potential promise for clinical application in treating patients with autoimmune diseases.
|
30631042 |
2019 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Tumor necrosis factor receptor 1 (TNFR1) is a central mediator of the inflammatory pathway and is associated with several autoimmune diseases such as rheumatoid arthritis.
|
31363069 |
2019 |
|
Mental Depression
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
RESULTS Cerebellar fastigial nucleus stimulation reduced behaviors associated with depression in the rat model, upregulated the expression of miR-29c, and reduced the expression of TNFRSF1A and inflammatory cytokines, and mildly reduced neuronal apoptosis.
|
31352465 |
2019 |
|
Mental Depression
|
0.360 |
Biomarker
|
disease |
BEFREE |
Stress-related suppression of TNFα predicted drinking severity only in alcohol-dependent individuals with subclinical depression, and suppressed TNFR1 following stress was only seen in individuals with subclinical depression.
|
31736187 |
2019 |
|
Depressive disorder
|
0.360 |
Biomarker
|
disease |
BEFREE |
Stress-related suppression of TNFα predicted drinking severity only in alcohol-dependent individuals with subclinical depression, and suppressed TNFR1 following stress was only seen in individuals with subclinical depression.
|
31736187 |
2019 |